当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
KEDRAB, Rabies Immune Globulin (Human)
药品名称
KEDRAB, Rabies Immune Globulin (Human)
承诺描述
Deferred pediatric study under PREA for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrently with a full course of rabies vaccine in pediatric patients ages 0 months to less than 17 years.
承诺状态描述
The final report was submitted to FDA on July 16, 2020.
报告接收日期
2020/10/30 0:00:00